AI assistant
Anbio Biotechnology — Proxy Solicitation & Information Statement 2026
Apr 27, 2026
31914_ffr_2026-04-27_229e390e-6584-41a4-b409-802557e04d42.zip
Proxy Solicitation & Information Statement
Open in viewerOpens in your device viewer
6-K 1 anbio6k042226.htm FORM 6-K
Field: Rule-Page
Field: /Rule-Page
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
Field: Rule-Page
Field: /Rule-Page
FORM 6-K
Field: Rule-Page
Field: /Rule-Page
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of April 2026
Commission File Number: 001-42526
Anbio Biotechnology
Friedrich-Ebert-Anlage 35-37, 60327 Frankfurt am Main, Germany +49 69870039170
(Address, including zip code, and telephone number, including area code, of Registrant’s principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Form 20-F ☒ Form 40-F ☐
Field: Rule-Page
Field: /Rule-Page
Field: Page; Sequence: 1
Field: /Page
INFORMATION CONTAINED IN THIS FORM 6-K REPORT
In connection with the extraordinary general meeting of shareholders of Anbio Biotechnology (the “Company”), attached hereto and incorporated by reference herein are Notice of Meetings of Shareholders and Proxy Statement and Form of Proxy Card.
Field: Page; Sequence: 2; Options: NewSection; Value: 1
Field: Sequence; Type: Arabic; Name: PageNo 1 Field: /Sequence
Field: /Page
EXHIBIT INDEX
| Exhibit No. | Description |
|---|---|
| 99.1 | Notice of Meetings of Shareholders and Proxy Statement |
| 99.2 | Form of Proxy Card for the Meeting of Shareholders |
| of Class A Ordinary Shares | |
| 99.3 | Form of Proxy Card for the Meeting of Shareholders |
| of Class A Ordinary Shares and Class B Ordinary Shares | |
| 99.4 | Amended and Restated Memorandum and Articles of Association |
Field: Page; Sequence: 3; Value: 1
Field: Sequence; Type: Arabic; Name: PageNo 2 Field: /Sequence
Field: /Page
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Anbio Biotechnology — By: | /s/
Michael Lau |
| --- | --- |
| Name: | Michael Lau |
| Title: | Chief Executive Officer |
Field: Page; Sequence: 4; Options: Last
Field: Sequence; Type: Arabic; Name: PageNo 3 Field: /Sequence
Field: /Page